- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Healthcare Businesswomen's Association Names 2023 Award Recipients
The HBA announced the 2023 Woman of the Year, Honorable Mentor, and STAR recipients.
The Healthcare Businesswomen’s Association (HBA) announces the 2023 Woman of the Year, Honorable Mentor, and STAR. Recognized for their outstanding contributions to healthcare and the advancement of women in the workplace, the honorees will be celebrated at HBA’s 33rd annual Woman of the Year event on May 16 in New York City and virtually around the globe.
Christi Shaw, Chief Executive Officer, Kite, a Gilead Company, was selected as the 2023 Woman of the Year. Jag Dosanjh, President, U.S. Neuroscience and Eye Care, AbbVie, is the recipient of the Honorable Mentor award. Liz Paulson, Associate Vice President, Life Sciences for the Healthcare Business of LexisNexis® Risk Solutions, is recognized with HBA’s Strategic Transformation Achievement Recognition (STAR) volunteer honor.
For inquiries about a media pass to HBA’s Woman of the Year event; interview opportunities; or information about HBA’s signature award programs, please contact nwhite@HBAnet.org or visit HBAnet.org/awards.
Continue reading this story here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
